A Pilot Study of Acupoint Injection for Primary Dysmenorrhea (DAT)
Primary Purpose
Dysmenorrhea, Pain, Menstrual
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vitamin K acupoint injection
Saline Injection
Sponsored by
About this trial
This is an interventional treatment trial for Dysmenorrhea focused on measuring acupuncture, menstrual pain, dysmenorrhea, menstrual cramps, vitamin K1
Eligibility Criteria
Inclusion Criteria:
- Young women age 18-25
- Severe primary dysmenorrhea (defined as severe, recurrent painful periods for 6 months or more, that are not due to any other diagnosis, and that have not been relieved, or have been only partially relieved by any other treatment)
- Nulliparous
- English speaking
- No acute or chronic conditions diagnosed or suspected
- Not on hormonal contraceptives
- Regular menstrual cycles for at least 6 months
- Has a working phone or pager
Exclusion Criteria:
- Use of hormonal contraceptives, or intra-uterine device
- Pregnancy
- Dysmenorrhea due to any other suspected or recognized causes
- History of abdominal surgery
- Participation in other concomitant therapy for acute or chronic pain
- Current treatment with anti-coagulant drugs for any reason
- Previous treatment with vitamin K acupoint injection
- Plans to be out of area during next 5 months
- Under age 18
- Known allergy to Vitamin K.
Sites / Locations
- Mount Zion Outpatient Unit
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Vitamin K acupoint injection
Saline Injection
Arm Description
Participants will receive the vitamin K intervention within 2 days of the onset of painful menstrual cramps.
Participants will receive the saline treatment within 2 days of the onset of painful menstrual cramps.
Outcomes
Primary Outcome Measures
self-reported pain
Secondary Outcome Measures
medications used during menstrual cycle
activity restriction
vitamin K content in blood
Cox retrospective symptom scale
Full Information
NCT ID
NCT00995917
First Posted
October 14, 2009
Last Updated
April 18, 2012
Sponsor
University of California, San Francisco
1. Study Identification
Unique Protocol Identification Number
NCT00995917
Brief Title
A Pilot Study of Acupoint Injection for Primary Dysmenorrhea
Acronym
DAT
Official Title
A Randomized, Crossover, Pilot Trial of the Feasibility and Safety of Acupoint Injection of Vitamin K for Treatment of Primary Dysmenorrhea
Study Type
Interventional
2. Study Status
Record Verification Date
April 2012
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
July 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Many women, particularly adolescent women, suffer from painful menstrual cramps, medically referred to as dysmenorrhea. Common treatments for menstrual cramps are non-steroidal anti-inflammatory drugs and oral contraceptives, but both have side effects that limit their use. Injection of vitamin K into an acupuncture point has been used as treatment for dysmenorrhea at the Obstetrics & Gynecology Hospital in Shanghai, China since at least 1985. More research is needed on the effectiveness of this treatment and its acceptability to different women. The objective of this study is to examine the feasibility and effectiveness of acupoint injection of vitamin K1 for the treatment of severe primary dysmenorrhea in the United States. Twenty participants will be randomized to receive either 1) vitamin K1 injection into an acupuncture point at the start of their menstrual cycle followed by a saline injection in a non-acupuncture point two months later or 2) saline injection in a non-acupuncture point followed by vitamin K1 injection into an acupuncture point two months later. The primary outcome measure will be change in pain intensity measured before and after each treatment. Data on other menstrual symptoms will be collected by telephone or a web-based survey. Three additional participants will be recruited to receive vitamin K1 injection into an acupuncture point and have blood samples drawn before and after injection to determine absorption of vitamin K1. The aims of the study are to collect preliminary data on the efficacy and safety of vitamin K1 injected in an acupoint for the treatment of severe primary dysmenorrhea; assess the feasibility and acceptability of the treatment among U.S. women; and test the blood absorption of vitamin K1 following acupoint injection treatment.
The investigators hypothesize that:
Vitamin K1 acupoint injection is a safe treatment for women with menstrual pain.
Vitamin K1 acupoint injection reduces menstrual pain more than placebo saline injection does.
The treatment of vitamin K1 acupoint injection is acceptable to U.S. women.
Vitamin K1 is absorbed into the blood thru acupoint injection.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dysmenorrhea, Pain, Menstrual
Keywords
acupuncture, menstrual pain, dysmenorrhea, menstrual cramps, vitamin K1
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
18 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vitamin K acupoint injection
Arm Type
Experimental
Arm Description
Participants will receive the vitamin K intervention within 2 days of the onset of painful menstrual cramps.
Arm Title
Saline Injection
Arm Type
Sham Comparator
Arm Description
Participants will receive the saline treatment within 2 days of the onset of painful menstrual cramps.
Intervention Type
Other
Intervention Name(s)
Vitamin K acupoint injection
Intervention Description
Vitamin K will be injected into an acupuncture point within 2 days of the onset of painful menstrual cramps. Injections of 5 mg/0.5ml of vitamin K1 will be administered in bilateral acupuncture points. A single shot of vitamin K1 is 10mg/ml. Five mg/0.5ml will be drawn twice from one ampule and injected into each bilateral site, for a total dose of 10mg/ml of vitamin K.
Intervention Type
Other
Intervention Name(s)
Saline Injection
Intervention Description
Injection of .5ml saline bilaterally into both legs within 2 days of the onset of painful menstrual cramps.
Primary Outcome Measure Information:
Title
self-reported pain
Time Frame
3-5 months
Secondary Outcome Measure Information:
Title
medications used during menstrual cycle
Time Frame
3-5 months
Title
activity restriction
Time Frame
3-5 months
Title
vitamin K content in blood
Time Frame
1-2 months
Title
Cox retrospective symptom scale
Time Frame
3-5 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Young women age 18-25
Severe primary dysmenorrhea (defined as severe, recurrent painful periods for 6 months or more, that are not due to any other diagnosis, and that have not been relieved, or have been only partially relieved by any other treatment)
Nulliparous
English speaking
No acute or chronic conditions diagnosed or suspected
Not on hormonal contraceptives
Regular menstrual cycles for at least 6 months
Has a working phone or pager
Exclusion Criteria:
Use of hormonal contraceptives, or intra-uterine device
Pregnancy
Dysmenorrhea due to any other suspected or recognized causes
History of abdominal surgery
Participation in other concomitant therapy for acute or chronic pain
Current treatment with anti-coagulant drugs for any reason
Previous treatment with vitamin K acupoint injection
Plans to be out of area during next 5 months
Under age 18
Known allergy to Vitamin K.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria Chao, Dr PH, MPA
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mount Zion Outpatient Unit
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
11358700
Citation
Davis AR, Westhoff CL. Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J Pediatr Adolesc Gynecol. 2001 Feb;14(1):3-8. doi: 10.1016/s1083-3188(00)00076-0.
Results Reference
background
PubMed Identifier
12380631
Citation
Milsom I, Minic M, Dawood MY, Akin MD, Spann J, Niland NF, Squire RA. Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies. Clin Ther. 2002 Sep;24(9):1384-400. doi: 10.1016/s0149-2918(02)80043-1.
Results Reference
background
PubMed Identifier
15994623
Citation
Davis AR, Westhoff C, O'Connell K, Gallagher N. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol. 2005 Jul;106(1):97-104. doi: 10.1097/01.AOG.0000165826.03915.65.
Results Reference
background
Citation
Yu J. Efficacy of vitamin K3 in the treatment of functional dysmenorrhoea: Clinical and laboratory observations. New Medicine and Clinical Trial. 1985:4
Results Reference
background
PubMed Identifier
8917003
Citation
Harlow SD, Park M. A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women. Br J Obstet Gynaecol. 1996 Nov;103(11):1134-42. doi: 10.1111/j.1471-0528.1996.tb09597.x. Erratum In: Br J Obstet Gynaecol 1997 Mar;104(3):386.
Results Reference
background
Learn more about this trial
A Pilot Study of Acupoint Injection for Primary Dysmenorrhea
We'll reach out to this number within 24 hrs